1. [CASE 1 -- QUESTION 1] Which of the following most accurately identifies the foods that were pharmacologically relevant to this presentation, the molecular mechanism producing the hypertensive crisis, and why the troponin elevation requires specific pharmacological consideration in management?

• A) All four foods contributed equally to the crisis -- phenelzine non-selectively inhibits intestinal MAO-A for all dietary amines including tyramine (aged Gruyere, Chianti, salami, fermented black bean paste), and all of these foods contain tyramine at similar concentrations; the troponin elevation reflects stress cardiomyopathy (Takotsubo) from the catecholamine surge and does not require any modification of antihypertensive management since Takotsubo cardiomyopathy resolves spontaneously once the catecholamine excess is controlled.
• B) The pharmacologically relevant foods are the aged Gruyere (highest tyramine content among cheeses), the Chianti wine reduction (red wine contains significant tyramine), the house-cured salami (cured meats are among the highest tyramine sources), and the fermented black bean paste (fermented soy products contain tyramine) -- all four are high-tyramine foods; the molecular mechanism is phenelzine-mediated abolition of intestinal MAO-A, allowing large amounts of tyramine to bypass first-pass inactivation, enter sympathetic terminals via NET, displace vesicular NE via VMAT2, and produce massive NE release through reverse NET transport; phenelzine simultaneously prevents intraneuronal MAO-A from degrading cytoplasmic NE, amplifying the surge; the troponin elevation reflects catecholamine-induced myocardial injury (type 2 MI or stress cardiomyopathy) and mandates that beta-blockade (which might be considered for hypertension) be avoided without prior alpha-blockade to prevent unopposed alpha-1 vasoconstriction worsening both hypertension and myocardial ischemia.
• C) Only the Chianti wine reduction is pharmacologically relevant -- wine is uniquely dangerous in MAOI-treated patients because it contains both tyramine and alcohol; alcohol independently inhibits MAO by competing for the FAD cofactor binding site, synergizing with phenelzine's MAO inhibition; the aged cheese, salami, and fermented bean paste would have been safely inactivated by residual MAO-B activity in the intestinal wall (since MAO-B is not inhibited by phenelzine); the troponin elevation is from alcohol-induced myocardial toxicity and not relevant to the antihypertensive choice.
• D) The molecular mechanism involves phenelzine inhibiting intestinal MAO-A and allowing dietary tyramine from the aged cheese, salami, and fermented black bean paste to reach the systemic circulation -- the Chianti wine reduction is not a significant tyramine source because cooking the wine for the reduction process destroys tyramine through heat denaturation; the troponin elevation from catecholamine-induced myocardial injury requires that IV esmolol (cardioselective beta-1 blocker) be the first-line antihypertensive chosen rather than nitroprusside, since esmolol addresses both the hypertension and the catecholamine-mediated myocardial injury simultaneously.

2. [CASE 1 -- QUESTION 2] The emergency team administers IV phentolamine 5 mg bolus. BP decreases from 236/148 to 168/98 mmHg within 5 minutes. Heart rate increases from 112 to 134 bpm. Which of the following most accurately explains the mechanism of the tachycardia that accompanies phentolamine administration in this setting, and why this differs from the expected heart rate response to blood pressure reduction by other antihypertensives?

• A) Phentolamine blocks alpha-1 receptors on the SA node, removing direct sympathetic alpha-1 inhibition of pacemaker cells -- the disinhibited SA node then increases its intrinsic firing rate; the tachycardia from SA node alpha-1 disinhibition is unique to phentolamine and does not occur with beta-blockers or calcium channel blockers that lower blood pressure by different mechanisms.
• B) Phentolamine is a non-selective alpha-adrenergic blocker (blocking both alpha-1 and alpha-2 receptors) -- alpha-1 blockade causes peripheral vasodilation and blood pressure reduction, triggering a baroreceptor reflex that increases sympathetic outflow to the SA node (beta-1 receptor-mediated tachycardia); simultaneously, alpha-2 blockade on sympathetic nerve terminals removes the presynaptic autoreceptor-mediated inhibition of NE release, disinhibiting NE release at all sympathetic terminals including cardiac sympathetic terminals -- this combined baroreflex-driven AND alpha-2-disinhibited NE release produces greater tachycardia than would occur with a selective alpha-1 blocker (like prazosin) that preserves alpha-2 autoreceptor feedback; in this catecholamine-excess state, the disinhibited NE release from abundant vesicular stores makes the phentolamine-induced tachycardia particularly pronounced.
• C) Phentolamine directly activates beta-1 adrenergic receptors at the SA node through partial agonist activity at the catecholamine binding site -- this direct beta-1 partial agonism is the primary mechanism of phentolamine-induced tachycardia, which is independent of blood pressure reduction and baroreflex activation; the tachycardia can be reversed by adding a beta-1 selective blocker (metoprolol) after alpha-1 receptor-mediated blood pressure has been controlled.
• D) Phentolamine-induced tachycardia in a MAOI-tyramine crisis is uniquely dangerous because phenelzine's MAO inhibition prevents the degradation of the NE released by the reflex sympathetic surge -- the tachycardia-associated NE is therefore not degraded by intraneuronal MAO-A after reuptake, allowing each unit of NE to repeatedly re-enter the synapse through reverse NET transport; this recycling amplifies the tachycardia far beyond what would be expected from baroreflex activation alone in a patient not on an MAOI.

3. [CASE 1 -- QUESTION 3] The patient is stabilized and his psychiatrist is consulted. He asks whether the patient can be switched to a selective serotonin reuptake inhibitor (SSRI) such as sertraline to eliminate the tyramine dietary restriction. The psychiatrist notes that phenelzine was chosen after two failed SSRI trials and one failed SNRI trial. The patient asks how long after stopping phenelzine he must wait before starting sertraline. Which of the following most accurately explains the required washout period and its pharmacological basis?

• A) No washout period is required between phenelzine and sertraline because phenelzine is a selective MAO-B inhibitor that does not affect serotonin metabolism -- SSRIs can be started immediately after phenelzine discontinuation; serotonin syndrome risk exists only when switching from non-selective MAOIs to SSRIs, not when switching from MAO-B selective inhibitors.
• B) Phenelzine is a hydrazine irreversible non-selective MAOI -- after discontinuation, MAO enzyme activity recovers only as new MAO protein is synthesized; this takes approximately 14 days (2 weeks) for clinically relevant MAO-A recovery; during this 14-day washout, dietary tyramine restriction must be maintained; after 14 days, sertraline can be started; if sertraline were started during the washout, the combination of MAO-A inhibition (preventing serotonin degradation) and SSRI-mediated serotonin reuptake blockade (increasing synaptic serotonin) would produce serotonin syndrome -- potentially fatal from hyperthermia, neuromuscular excitability (clonus, hyperreflexia, tremor), and autonomic instability (tachycardia, diaphoresis, labile blood pressure).
• C) Phenelzine requires a 5 half-life washout period like all psychiatric medications -- phenelzine's elimination half-life is approximately 2 hours, so 5 half-lives equals 10 hours; sertraline can safely be started 12 hours after the last phenelzine dose; this short washout reflects the pharmacokinetic elimination of phenelzine itself rather than the duration of MAO inhibition, since phenelzine is a reversible competitive inhibitor that dissociates from MAO within hours of drug clearance.
• D) Phenelzine discontinuation requires a 14-day washout before starting any serotonergic drug because phenelzine irreversibly inhibits MAO-A; MAO-A is the primary enzyme responsible for intraneuronal serotonin degradation; recovery of MAO-A activity requires synthesis of new MAO-A protein over approximately 14 days; if sertraline is started before MAO-A activity has recovered, serotonin reuptake blockade (reducing serotonin removal from the synapse) combined with MAO-A inhibition (reducing intraneuronal serotonin degradation after reuptake) produces serotonin syndrome through excess serotonergic neurotransmission at 5-HT1A and 5-HT2A receptors; the clinical syndrome is characterized by the Hunter Criteria triad of neuromuscular abnormalities (clonus, hyperreflexia, tremor, myoclonus), autonomic instability (hyperthermia, tachycardia, diaphoresis), and altered mental status; cyproheptadine (5-HT2A antagonist) plus supportive care is the treatment.

4. [CASE 1 -- QUESTION 4] Three months after the tyramine crisis, the patient is now stable on tranylcypromine (a non-hydrazine irreversible MAOI). His cardiologist wishes to perform a cardiac stress test and asks about the safety of dobutamine pharmacological stress testing in a patient on a non-selective MAOI. Which of the following most accurately predicts the pharmacodynamic interaction between tranylcypromine and dobutamine?

• A) Dobutamine is a direct beta-1 and beta-2 adrenergic agonist that does not require uptake into sympathetic nerve terminals or vesicular release to produce its effects -- it acts directly on beta receptors; tranylcypromine's MAOI effect is therefore irrelevant to dobutamine pharmacology because MAO degrades catecholamines after reuptake, not before receptor activation; dobutamine pharmacological stress testing is safe in MAOI-treated patients at standard doses without any dose modification.
• B) Dobutamine is a direct-acting synthetic catecholamine (beta-1 selective with some beta-2 and mild alpha-1 activity) that activates adrenergic receptors directly without requiring NET uptake or vesicular release -- however, after receptor activation and dissociation, dobutamine is taken up by NET and degraded by intraneuronal MAO-A; tranylcypromine inhibits this intraneuronal MAO-A, reducing dobutamine clearance from the nerve terminal and prolonging its circulatory half-life; the interaction is therefore pharmacokinetic (reduced dobutamine clearance) rather than pharmacodynamic; dobutamine doses should be reduced by approximately 50% in MAOI-treated patients to account for this clearance reduction.
• C) Dobutamine pharmacological stress testing carries enhanced risk in patients on non-selective MAOIs because dobutamine, while primarily a direct-acting catecholamine, has some indirect sympathomimetic properties and is metabolized by COMT and MAO-A; tranylcypromine inhibition of MAO-A reduces dobutamine metabolism, potentially prolonging its effects; however, the greater risk is the additive catecholamine sensitization from chronic MAOI treatment -- chronic MAO inhibition leads to upregulation of postsynaptic adrenergic receptors throughout the cardiovascular system, producing enhanced sensitivity to any catecholamine stimulus; standard dobutamine doses may produce exaggerated hemodynamic responses and increase the risk of arrhythmia and ischemia during stress testing; exercise stress testing (if physically feasible) is generally preferred over pharmacological stress testing with catecholamine-based agents in MAOI-treated patients.
• D) The pharmacodynamic interaction between tranylcypromine and dobutamine depends critically on whether dobutamine has any indirect sympathomimetic activity -- pure direct agonists at adrenergic receptors are not potentiated by MAO inhibition; review of dobutamine's mechanism confirms it acts exclusively through direct receptor activation with no NET uptake, no vesicular displacement of NE, and no reverse transport; the only pharmacological consideration is that if dobutamine infusion is accompanied by the standard clinical protocol of incremental dose increases until target heart rate is achieved, the already-elevated heart rate in a sympathetically sensitized MAOI patient may cause the target to be reached at lower dobutamine doses than in non-MAOI patients.

5. [CASE 2 -- QUESTION 1] Which of the following most accurately explains the pathophysiological mechanism of the repetitive nerve stimulation finding, the molecular target of the AChR antibodies, and why the edrophonium test is positive in this patient?

• A) The 42% decremental response on repetitive nerve stimulation reflects impaired presynaptic ACh synthesis -- AChR antibodies in this patient target choline acetyltransferase (ChAT) rather than the receptor itself, reducing ACh synthesis during high-demand stimulation; edrophonium is positive because inhibiting AChE allows the reduced ACh produced by impaired ChAT to accumulate and compete more effectively at the remaining functional NM receptors; the repetitive nerve stimulation decrement reflects this presynaptic synthesis failure rather than a postsynaptic receptor deficit.
• B) The 42% decremental response on repetitive nerve stimulation reflects a postsynaptic NMJ safety factor failure -- AChR antibodies (predominantly IgG1 and IgG3) bind to the alpha subunit of the NM nicotinic receptor at or near the ACh binding site; antibody binding reduces functional NM receptor numbers through three mechanisms: direct receptor blockade (competitive inhibition of ACh binding), complement-mediated destruction of the postsynaptic membrane (endplate myopathy), and accelerated internalization/degradation of crosslinked receptor dimers; during repetitive stimulation at 3 Hz, the normal decline in quantal ACh release per impulse (normal presynaptic depression) reduces the amount of ACh released with each successive stimulus; in health, this is inconsequential because the NMJ safety factor (ratio of end plate potential amplitude to threshold) is large; in MG with reduced postsynaptic AChR density, the safety factor is reduced and the presynaptic ACh decline with repetitive stimulation causes successive end plate potentials to fall below threshold for muscle action potential generation in an increasing fraction of fibers -- producing the decremental CMAP; edrophonium inhibits AChE in the cleft, allowing ACh to accumulate and re-activate remaining NM receptors with each impulse, transiently restoring end plate potential amplitude above threshold and producing the positive Tensilon test.
• C) The 42% decremental response on repetitive nerve stimulation is pathognomonic for Lambert-Eaton myasthenic syndrome (LEMS) rather than myasthenia gravis -- in MG, repetitive nerve stimulation produces an incremental (facilitating) response because postsynaptic antibody binding paradoxically enhances vesicular ACh release; the AChR antibody titer in this patient likely reflects a non-specific immunological marker rather than the pathological antibody; LEMS antibodies (anti-VGCC) should be measured, and the correct diagnosis would guide different treatment (3,4-DAP for LEMS rather than pyridostigmine for MG).
• D) The decremental response reflects failure of the muscle fiber action potential to propagate along the T-tubule system due to antibody-mediated disruption of voltage-gated sodium channels at the T-tubule membrane -- AChR antibodies in MG cross-react with sodium channel beta subunits, disrupting T-tubule excitation; edrophonium's positive test in this setting reflects its direct sodium channel-stabilizing effect rather than AChE inhibition, since inhibiting AChE would not help a purely T-tubule conduction problem.

6. [CASE 2 -- QUESTION 2] The neurologist starts pyridostigmine 60 mg every 4 hours (five times daily). Three weeks later the patient reports significant improvement in ptosis and swallowing but develops abdominal cramping, diarrhea, and increased salivation after each dose. Which of the following most accurately explains the mechanism of these side effects, why they occur specifically with pyridostigmine dosing, and what management strategy best addresses them while maintaining therapeutic efficacy at the NMJ?

• A) The GI side effects are caused by pyridostigmine crossing the blood-brain barrier and activating central muscarinic M1 receptors in the dorsal vagal complex, increasing parasympathetic outflow to the GI tract -- since pyridostigmine is a quaternary ammonium compound that cannot cross lipid membranes, these central effects are paradoxical and actually reflect a recently discovered active transport mechanism for pyridostigmine across the blood-brain barrier that is upregulated in patients with autoimmune disease; glycopyrrolate (quaternary anticholinergic that also cannot cross the BBB) would block these centrally-mediated GI effects.
• B) Pyridostigmine inhibits acetylcholinesterase throughout the body, not selectively at the NMJ -- AChE inhibition at peripheral muscarinic synapses (GI smooth muscle, salivary glands, GI secretory glands) allows ACh to accumulate at M3 receptors, increasing intestinal smooth muscle contractility (producing cramping and diarrhea) and increasing salivary and GI gland secretion; these muscarinic side effects occur at all cholinergic synapses where pyridostigmine reaches adequate concentration; the temporal pattern (side effects peaking 45-60 minutes after each dose, correlating with peak pyridostigmine plasma levels) distinguishes dose-related muscarinic effects from cholinergic crisis; management: glycopyrrolate (a quaternary muscarinic antagonist that does not cross the BBB, avoiding CNS anticholinergic side effects) taken 30 minutes before pyridostigmine can blunt the peak muscarinic effects; alternatively, pyridostigmine extended-release (Mestinon Timespan) reduces peak plasma fluctuations.
• C) The GI side effects represent cholinergic crisis from excess pyridostigmine -- the absence of fasciculations and muscle weakness argues against NMJ cholinergic crisis, but GI-restricted cholinergic crisis can occur when pyridostigmine accumulates preferentially in the enteric nervous system due to its poor systemic absorption; dose reduction of pyridostigmine to 30 mg every 4 hours is the appropriate management, accepting some reduction in NMJ efficacy to prevent progression to full cholinergic crisis with NMJ involvement.
• D) The side effects occur because pyridostigmine also inhibits butyrylcholinesterase (BuChE, pseudocholinesterase) in the plasma -- BuChE-inhibition leads to accumulation of acetylcholine esters and choline in the bloodstream; these circulating cholinergic substances then activate peripheral muscarinic receptors in the GI tract through a humoral (non-synaptic) mechanism; the management is plasma infusion to supply fresh BuChE to metabolize the accumulated cholinergic substances, restoring the normal cholinergic balance while pyridostigmine continues to provide therapeutic NMJ AChE inhibition.

7. [CASE 2 -- QUESTION 3] The veteran is scheduled for elective laparoscopic cholecystectomy. The anesthesiologist reviews his medication list showing pyridostigmine 60 mg five times daily. She must plan the anesthetic carefully because of the pharmacological interactions between pyridostigmine and neuromuscular blocking agents. Which of the following most accurately predicts the pharmacological interactions and guides the anesthetic plan?

• A) Pyridostigmine has no significant interaction with non-depolarizing neuromuscular blockers because pyridostigmine acts at the presynaptic AChE while non-depolarizing blockers act at the postsynaptic NM receptor -- these are entirely separate molecular targets with no pharmacodynamic interaction; the MG patient can receive standard doses of rocuronium for intubation and standard reversal with neostigmine at the end of the case.
• B) In MG patients on pyridostigmine, the key anesthetic considerations are: (1) enhanced sensitivity to non-depolarizing NM blockers (reduced NMJ safety factor means even small amounts of competitive NM blockade can produce complete neuromuscular block -- use dramatically reduced doses, e.g. one-tenth of the standard intubating dose, and monitor with quantitative neuromuscular monitoring; rocuronium 0.3 mg/kg rather than 1.2 mg/kg for intubation); (2) pyridostigmine has already increased NMJ AChE inhibition, so adding neostigmine for reversal risks cholinergic excess -- sugammadex (encapsulates rocuronium, providing reversal independent of AChE inhibition) is the preferred reversal agent; (3) succinylcholine should be avoided -- pyridostigmine inhibits plasma pseudocholinesterase (which hydrolyzes succinylcholine), producing prolonged succinylcholine block; and (4) the patient may require postoperative ventilatory support given unpredictable NMJ recovery in MG.
• C) MG patients should receive higher-than-normal doses of non-depolarizing NM blockers because the circulating AChR antibodies provide competitive antagonism at the NM receptor that must be overcome by the drug for adequate surgical relaxation -- this antibody-drug competition requires dose escalation; succinylcholine is the preferred depolarizing blocker in MG because MG patients have upregulated (not downregulated) extrajunctional AChR, producing an exaggerated depolarizing response that provides excellent intubating conditions; pyridostigmine should be held the morning of surgery to reduce NMJ AChE inhibition.
• D) The anesthesiologist should avoid all neuromuscular blocking agents in this MG patient and use a total intravenous anesthesia (TIVA) technique with propofol and remifentanil, supplemented by high-dose volatile anesthetic (sevoflurane) to achieve the muscle relaxation needed for laparoscopy -- volatile anesthetics themselves produce sufficient neuromuscular blockade for laparoscopic surgery through their direct effects on the NM receptor; if any NM blocker is required, mivacurium (which is hydrolyzed by pseudocholinesterase like succinylcholine) is preferred because its metabolism is unaffected by pyridostigmine.

8. [CASE 2 -- QUESTION 4] Three months after cholecystectomy, the patient develops a myasthenic crisis requiring ICU admission and mechanical ventilation. He is treated with plasma exchange (5 sessions over 10 days) and intravenous immunoglobulin (IVIG). Which of the following most accurately explains the distinct mechanisms by which plasma exchange and IVIG each modulate the autoimmune process in MG, and identifies the clinical scenario in which each is preferred?

• A) Plasma exchange and IVIG both work by the same mechanism -- passive immunization with pooled normal IgG from thousands of donors; IVIG provides normal IgG that competitively displaces pathological AChR antibodies from their NM receptor binding sites; plasma exchange removes only non-immunoglobulin plasma proteins (complement factors, cytokines) and does not remove AChR antibodies; IVIG is therefore superior in acute crisis because it directly addresses the pathological antibody; plasma exchange is used only when IVIG is unavailable.
• B) Plasma exchange (plasmapheresis) physically removes circulating pathological AChR antibodies from the plasma by replacing patient plasma with albumin solution or fresh frozen plasma -- this produces rapid reduction in antibody titer over 5-14 days; it is preferred when very rapid onset of effect is needed (pre-thymectomy, severe acute crisis with respiratory failure, crisis unresponsive to other treatments) but its effect is transient (weeks) as B cells continue producing new antibodies; IVIG provides pooled IgG from thousands of donors that reduces pathological antibody activity through multiple mechanisms: Fc receptor saturation on macrophages (reducing AChR antibody-mediated effector functions), inhibition of complement activation, idiotypic network modulation (anti-idiotype antibodies in the IVIG pool binding to and neutralizing the patient's AChR antibodies), and reduction of new pathological antibody production; IVIG onset is slightly slower (days) than plasma exchange; both are short-term bridge therapies (weeks of benefit) -- neither provides durable immunosuppression; long-term disease control requires corticosteroids and steroid-sparing immunosuppressants (azathioprine, mycophenolate mofetil).
• C) IVIG works by providing anti-AChR antibodies derived from donors who were previously vaccinated against acetylcholine receptor -- these neutralizing antibodies bind to the patient's AChR antibodies and form immune complexes that are cleared by the reticuloendothelial system; plasma exchange removes these immune complexes along with the pathological antibodies, explaining why the two treatments are complementary and often used sequentially; the correct sequence is IVIG first (to neutralize antibodies) followed immediately by plasma exchange (to remove the immune complexes formed by the IVIG).
• D) Plasma exchange removes AChR antibodies rapidly (onset hours to days) and is preferred in life-threatening crisis; IVIG modulates the immune response through multiple mechanisms over days; both provide only short-term benefit of weeks duration; neither should be used alone in MG crisis without simultaneously initiating or optimizing long-term immunosuppressive therapy (corticosteroids, azathioprine, mycophenolate mofetil) to prevent recurrence once the acute bridge effect wanes; thymectomy (if thymoma is present or even in non-thymoma generalized MG in patients under age 65) provides long-term remission benefit and should be part of the comprehensive MG management plan.